KM
Therapeutic Areas
Incyclix Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INX-315 | CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer; CCNE1-Amplified Solid Tumors | Phase 1/2 |
Leadership Team at Incyclix Bio
PR
Patrick Roberts, Pharm.D., Ph.D.
Chief Executive Officer, Co-Founder
JS
Jay Strum, Ph.D.
Chief Scientific Officer, Co-Founder
JB
John Bisi, B.S.
Senior Vice President of Research and Development, Co-Founder
AB
Andrew Beelen, MD
Vice President of Clinical Development